MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding MoonLake Immunotherapeutics changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 114 | 2 | 111 | −1 |
| Shares | 59.5M | 21.7K | 60.8M | +1.32M (+2.2%) |
| Value | $2.99B | $1.09M | $2.67B | −$314.3M (−10.5%) |
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 750,000 | $33.0M | 3.80% |
| Camber Capital Management LP | 355,000 | $15.6M | 0.60% |
| Alyeska Investment Group, L.P. | 125,000 | $5.50M | 0.03% |
| Altium Capital Management LP | 115,000 | $5.06M | 2.09% |
| Eversept Partners, LP | 71,596 | $3.15M | 0.24% |
| Twinbeech Capital LP | 58,552 | $2.57M | 0.05% |
| Russell Investments Group, Ltd. | 33,559 | $1.48M | 0.00% |
| Capital Fund Management S.A. | 29,243 | $1.29M | 0.01% |
| Gsa Capital Partners LLP | 21,724 | $955.0K | 0.07% |
| Mirae Asset Global ETFs Holdings Ltd. | 16,730 | $735.6K | 0.00% |
| Jump Financial, LLC | 15,900 | $699.1K | 0.01% |
| Legal & General Group Plc | 15,790 | $694.3K | 0.00% |
| Hudson Bay Capital Management LP | 15,000 | $659.5K | 0.00% |
| Wexford Capital LP | 14,000 | $615.6K | 0.16% |
| Y-Intercept (Hong Kong) Ltd | 13,078 | $575.0K | 0.03% |
| PEAK6 Investments LLC | 13,000 | $571.6K | 0.03% |
| Engineers Gate Manager LP | 12,269 | $539.5K | 0.01% |
| Handelsbanken Fonder AB | 10,300 | $453.0K | 0.00% |
| Squarepoint Ops LLC | 7,340 | $322.7K | 0.00% |
| Simplex Trading, LLC | 2,118 | $93.0K | 0.00% |
| Planning Capital Management Corp | 2 | $88 | 0.00% |
| CWM, LLC | 5 | $0 | 0.00% |
Sold out (23)
Institutions that held MoonLake Immunotherapeutics at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (2)
Institutions that held MoonLake Immunotherapeutics at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 19,204 | $964.6K |
| Cutler Group LP | 2,500 | $125.0K |